Dec 12
This is part 2 of my article about predictions for the clinical trials industry in 2026. From my reporting on AI growing pains, site-network shakeups, and the never-ending sponsor–site tension over feasibility and budgets, it’s clear the industry is carrying plenty of unresolved business into the new year.
Read the full article featuring Rob DiCicco from Clinical Leader here.
Related Blog Posts
Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites
To kick off 2026, we spoke with industry experts and leaders in the Clinical Research News community about what they expect and look forward to in the new year. More than ever before, artificial intelligence took center stage. Read the full article featuring Allison Cuff Shimooka from Clinical Research News here.
Nearly a third of clinical trial procedures may not drive results
Clinical trial protocols are among the most complex and resource-intensive documents developed in pharmaceutical and biotechnology research. Designed to define objectives, procedures, participant criteria, and data collection practices, protocols serve as the operational blueprint for evaluating investigational therapies. However, as the range of study endpoints has grown, so too has the volume, complexity, and burden…
Working together to innovate on pragmatic clinical trials, with Rob DiCicco
Process innovation in the pharmaceutical industry is never easy, but its best chance of success comes when companies come together to work on big problems – especially when they bring in regulators and other stakeholders. Listen to the full podcast featuring Rob DiCicco by PharmaPhorum here.